Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment

the Hepatitis B Research Network (HBRN)

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Antiviral drug resistance hepatitis B virus (HBV) variants (HBV-DR) occur spontaneously in chronic hepatitis B (CHB) patients and after exposure to nucleos(t)ide analogues (NUCs). We determined the prevalence of HBV-DR variants among participants of the Hepatitis B Research Network (HBRN) Cohort Study conducted at 21 sites in the United States (US) and Canada. Samples obtained from 1342 CHB participants aged ≥18 years, and who were currently not receiving NUCs, were tested for HBV-DR variants by Sanger sequencing. In addition, next generation sequencing (NGS) was used to characterize HBV-DR variants from 66 participants with and 66 participants with no prior NUC exposure matched for HBV genotype and HBV DNA level. Half the participants were men, 75% Asian, 26% HBeAg positive. Primary HBV-DR variants were detected by Sanger sequencing in 16 (1.2%) participants: 2/142 (1.4%) with and 14/1200 (1.2%) without prior NUC exposure; only 1 of these 16 had a secondary variant. In total, 23 (1.7%) participants had secondary variants, including 1 with prior NUC experience. In the subset of 132 participants, NGS detected HBV-DR variants in a higher proportion of participants: primary variants in 18 (13.6%) (8 [12.1%] with, and 10 [15.2%] without prior NUC therapy) and secondary variants in 10 (7.6%) participants. Based on Sanger sequencing, prevalence of primary HBV-DR variants is low (1.2%) among adults with CHB in US/Canada. The similar low prevalence of HBV-DR variants in participants with and without NUC treatment suggests transmission of these variants is uncommon.

Original languageEnglish (US)
Pages (from-to)1032-1042
Number of pages11
JournalJournal of Viral Hepatitis
Volume24
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Viral Drug Resistance
Chronic Hepatitis B
Hepatitis B
Hepatitis B virus
Antiviral Agents
Therapeutics
Canada
Hepatitis B e Antigens

Keywords

  • antiviral treatment
  • hepatitis B virus
  • next generation sequencing
  • nucleos(t)ide analogues
  • Sanger sequencing

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases
  • Virology

Cite this

Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment. / the Hepatitis B Research Network (HBRN).

In: Journal of Viral Hepatitis, Vol. 24, No. 11, 01.11.2017, p. 1032-1042.

Research output: Contribution to journalArticle

@article{ee3b64b1f14945daa5ec4d5e9d934bbe,
title = "Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment",
abstract = "Antiviral drug resistance hepatitis B virus (HBV) variants (HBV-DR) occur spontaneously in chronic hepatitis B (CHB) patients and after exposure to nucleos(t)ide analogues (NUCs). We determined the prevalence of HBV-DR variants among participants of the Hepatitis B Research Network (HBRN) Cohort Study conducted at 21 sites in the United States (US) and Canada. Samples obtained from 1342 CHB participants aged ≥18 years, and who were currently not receiving NUCs, were tested for HBV-DR variants by Sanger sequencing. In addition, next generation sequencing (NGS) was used to characterize HBV-DR variants from 66 participants with and 66 participants with no prior NUC exposure matched for HBV genotype and HBV DNA level. Half the participants were men, 75{\%} Asian, 26{\%} HBeAg positive. Primary HBV-DR variants were detected by Sanger sequencing in 16 (1.2{\%}) participants: 2/142 (1.4{\%}) with and 14/1200 (1.2{\%}) without prior NUC exposure; only 1 of these 16 had a secondary variant. In total, 23 (1.7{\%}) participants had secondary variants, including 1 with prior NUC experience. In the subset of 132 participants, NGS detected HBV-DR variants in a higher proportion of participants: primary variants in 18 (13.6{\%}) (8 [12.1{\%}] with, and 10 [15.2{\%}] without prior NUC therapy) and secondary variants in 10 (7.6{\%}) participants. Based on Sanger sequencing, prevalence of primary HBV-DR variants is low (1.2{\%}) among adults with CHB in US/Canada. The similar low prevalence of HBV-DR variants in participants with and without NUC treatment suggests transmission of these variants is uncommon.",
keywords = "antiviral treatment, hepatitis B virus, next generation sequencing, nucleos(t)ide analogues, Sanger sequencing",
author = "{the Hepatitis B Research Network (HBRN)} and Lok, {A. S.} and L. Ganova-Raeva and Y. Cloonan and L. Punkova and Lin, {H. H.S.} and Lee, {W. M.} and Ghany, {M. G.} and Lau, {Daryl T.Y.} and Chung, {Raymond T.} and Roberts, {Lewis R.} and Roberts, {Lewis Rowland} and {Di Bisceglie}, {Adrian M.} and Mauricio Melman and Janssen, {L. A.} and Wong, {David K.} and Joshua Juan and Jordan Feld and Colina Yim and Jenny Heathcote and Robert Perrillo and Son Do and Han, {Steven Huy B.} and Tran, {Tram T.} and Terrault, {Norah A.} and Mandana Khalili and Cooper, {Stewart L.} and Fontana, {Robert J.} and Naoky Tsai and Fried, {Michael W.} and Keyur Patel and Donna Evon and Carithers, {Robert C.} and Margaret Shuhart and Kowdley, {Kris V.} and Wang, {Chia C.} and Sterling, {Richard K.} and {Jake Liang}, T. and Hoofnagle, {Jay H.} and Edward Doo and Chang, {Kyong Mi} and Park, {Jang June} and Belle, {Steven H.} and Abdus Wahed and David Kleiner",
year = "2017",
month = "11",
day = "1",
doi = "10.1111/jvh.12732",
language = "English (US)",
volume = "24",
pages = "1032--1042",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment

AU - the Hepatitis B Research Network (HBRN)

AU - Lok, A. S.

AU - Ganova-Raeva, L.

AU - Cloonan, Y.

AU - Punkova, L.

AU - Lin, H. H.S.

AU - Lee, W. M.

AU - Ghany, M. G.

AU - Lau, Daryl T.Y.

AU - Chung, Raymond T.

AU - Roberts, Lewis R.

AU - Roberts, Lewis Rowland

AU - Di Bisceglie, Adrian M.

AU - Melman, Mauricio

AU - Janssen, L. A.

AU - Wong, David K.

AU - Juan, Joshua

AU - Feld, Jordan

AU - Yim, Colina

AU - Heathcote, Jenny

AU - Perrillo, Robert

AU - Do, Son

AU - Han, Steven Huy B.

AU - Tran, Tram T.

AU - Terrault, Norah A.

AU - Khalili, Mandana

AU - Cooper, Stewart L.

AU - Fontana, Robert J.

AU - Tsai, Naoky

AU - Fried, Michael W.

AU - Patel, Keyur

AU - Evon, Donna

AU - Carithers, Robert C.

AU - Shuhart, Margaret

AU - Kowdley, Kris V.

AU - Wang, Chia C.

AU - Sterling, Richard K.

AU - Jake Liang, T.

AU - Hoofnagle, Jay H.

AU - Doo, Edward

AU - Chang, Kyong Mi

AU - Park, Jang June

AU - Belle, Steven H.

AU - Wahed, Abdus

AU - Kleiner, David

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Antiviral drug resistance hepatitis B virus (HBV) variants (HBV-DR) occur spontaneously in chronic hepatitis B (CHB) patients and after exposure to nucleos(t)ide analogues (NUCs). We determined the prevalence of HBV-DR variants among participants of the Hepatitis B Research Network (HBRN) Cohort Study conducted at 21 sites in the United States (US) and Canada. Samples obtained from 1342 CHB participants aged ≥18 years, and who were currently not receiving NUCs, were tested for HBV-DR variants by Sanger sequencing. In addition, next generation sequencing (NGS) was used to characterize HBV-DR variants from 66 participants with and 66 participants with no prior NUC exposure matched for HBV genotype and HBV DNA level. Half the participants were men, 75% Asian, 26% HBeAg positive. Primary HBV-DR variants were detected by Sanger sequencing in 16 (1.2%) participants: 2/142 (1.4%) with and 14/1200 (1.2%) without prior NUC exposure; only 1 of these 16 had a secondary variant. In total, 23 (1.7%) participants had secondary variants, including 1 with prior NUC experience. In the subset of 132 participants, NGS detected HBV-DR variants in a higher proportion of participants: primary variants in 18 (13.6%) (8 [12.1%] with, and 10 [15.2%] without prior NUC therapy) and secondary variants in 10 (7.6%) participants. Based on Sanger sequencing, prevalence of primary HBV-DR variants is low (1.2%) among adults with CHB in US/Canada. The similar low prevalence of HBV-DR variants in participants with and without NUC treatment suggests transmission of these variants is uncommon.

AB - Antiviral drug resistance hepatitis B virus (HBV) variants (HBV-DR) occur spontaneously in chronic hepatitis B (CHB) patients and after exposure to nucleos(t)ide analogues (NUCs). We determined the prevalence of HBV-DR variants among participants of the Hepatitis B Research Network (HBRN) Cohort Study conducted at 21 sites in the United States (US) and Canada. Samples obtained from 1342 CHB participants aged ≥18 years, and who were currently not receiving NUCs, were tested for HBV-DR variants by Sanger sequencing. In addition, next generation sequencing (NGS) was used to characterize HBV-DR variants from 66 participants with and 66 participants with no prior NUC exposure matched for HBV genotype and HBV DNA level. Half the participants were men, 75% Asian, 26% HBeAg positive. Primary HBV-DR variants were detected by Sanger sequencing in 16 (1.2%) participants: 2/142 (1.4%) with and 14/1200 (1.2%) without prior NUC exposure; only 1 of these 16 had a secondary variant. In total, 23 (1.7%) participants had secondary variants, including 1 with prior NUC experience. In the subset of 132 participants, NGS detected HBV-DR variants in a higher proportion of participants: primary variants in 18 (13.6%) (8 [12.1%] with, and 10 [15.2%] without prior NUC therapy) and secondary variants in 10 (7.6%) participants. Based on Sanger sequencing, prevalence of primary HBV-DR variants is low (1.2%) among adults with CHB in US/Canada. The similar low prevalence of HBV-DR variants in participants with and without NUC treatment suggests transmission of these variants is uncommon.

KW - antiviral treatment

KW - hepatitis B virus

KW - next generation sequencing

KW - nucleos(t)ide analogues

KW - Sanger sequencing

UR - http://www.scopus.com/inward/record.url?scp=85021729548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021729548&partnerID=8YFLogxK

U2 - 10.1111/jvh.12732

DO - 10.1111/jvh.12732

M3 - Article

VL - 24

SP - 1032

EP - 1042

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 11

ER -